Brepocitinib is a drug which acts as a dual inhibitor of JAK1 and TYK2, and was developed for the treatment of plaque psoriasis. From Wikipedia
The TYK2/JAK1 pill delivered steroid-sparing benefits that underpin a planned early‑2026 FDA submission.
